A Multi-center Retrospective Study of INO Treating B-ALL

Prior treatment

• Any of the following cardiac conditions:
  • NYHA Class III or IV congestive heart failure;
  • Severe arrhythmia requiring treatment;
  • Uncontrolled hypertension or pulmonary hypertension despite standard therapy;
  • Unstable angina;
  • Myocardial infarction, bypass surgery, or stent placement within six months before cell retransfusion;
  • Clinically significant valvular disease;
  • Other cardiac conditions deemed unsuitable by the investigator;
• History of hypersensitivity to any component of the investigational product.

Other illness

• Active infection at screening.
• History of epilepsy, cerebellar disease, or other active central nervous system disorders;
• Other conditions deemed unsuitable for participation in this clinical trial by the investigator.

Other

• Life expectancy of less than three months;

• Age between ≥16 and ≤80 years at screening, no gender restrictions
• Be diagnosed with B-ALL
• Appropirate organ function, meeting the following criteria:
  • Aspartate aminotransferase (AST) ≤3 times the upper limit of normal (ULN);
  • Alanine aminotransferase (ALT) ≤3 times ULN;
  • Total bilirubin ≤2 times ULN (for patients with Gilbert's syndrome, total bilirubin ≤3.0 times ULN and direct bilirubin ≤1.5 times ULN);
  • Serum creatinine ≤1.5 times ULN, or creatinine clearance ≥60 mL/min (using the Cockcroft-Gault formula);
  • Left ventricular ejection fraction (LVEF) ≥50%;